FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or orga ...

Financial Data and Key Metrics Changes - As of September 30, 2023, the company reported cash and cash equivalents and investments of $101.1 million [15] - Research and development expenses for Q3 2023 were $24.2 million, an increase from $18.9 million in Q3 2022 [15] - General and administrative expenses decreased to $5.1 million in Q3 2023 from $6.6 million in Q3 2022 [49] - The net loss for Q3 2023 was $27.5 million, or $0.65 per share, compared to a net loss of $24.6 million, or $0.58 per share, in Q3 2022 [49] Business Line Data and Key Metrics Changes - The ongoing Phase 1B trial of SL-172154 in combination with PLD for platinum-resistant ovarian cancer has enrolled 16 patients, with 11 being evaluable for efficacy [70][90] - In the Phase 1A/B trial for AML and higher-risk MDS, 37 patients have received SL-172154, with one complete response observed in a TP53 mutant higher-risk MDS patient [105][107] Market Data and Key Metrics Changes - The company is focusing on high unmet medical needs in the oncology space, particularly in AML and higher-risk MDS, where there is a significant opportunity for accelerated development [71] - The competitive landscape for CD47 inhibitors has evolved, with several agents facing challenges, which may provide an opportunity for SL-172154 to differentiate itself [110] Company Strategy and Development Direction - The company aims to leverage its unique mechanism of action with SL-172154, which combines CD47 inhibition with CD40 activation, to improve response rates and durability in patients [88][77] - There is a focus on completing enrollment in ongoing trials and presenting data at upcoming conferences, including the ASH Annual Meeting [16][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the financial position, stating that current cash reserves are sufficient to fund operations through the end of 2024 [93] - The management team is optimistic about the potential of SL-172154 to meet unmet medical needs and is encouraged by the early clinical data [101][77] Other Important Information - The company plans to present complete data from the dose escalation portion of the trial at the ASH meeting and share initial data from frontline cohorts [48][50] - The safety profile of SL-172154 has been acceptable, with infusion-related reactions being the most common adverse event [90] Q&A Session Summary Question: Can you provide more detail about the baseline characteristics of patients in the PROC study? - The majority of patients (88%) had failed frontline platinum-containing regimens, with 100% having received platinum and 56% having received bevacizumab [51] Question: What is the expected response rate for the PLD plus SL-172154 combination? - A response rate in excess of 25% in an all-comer PROC setting could be meaningful, especially if accompanied by a duration of response exceeding five months [140] Question: Are there plans to use biomarker analysis in the PLD combo trial? - The company is collecting various biomarker data to analyze differences in responders and nonresponders [60] Question: What are the expectations for the TP53 mutant AML cohort? - There is potential for an accelerated path if the complete response rate exceeds 40%, which would be a good indicator for duration of response [112] Question: How does SL-172154 compare to other CD47 inhibitors in terms of efficacy? - The company is looking to demonstrate the impact of CD40 ligand on efficacy in responding patients, especially in the context of evolving competition in the CD47 space [95]

PIONEERING NOVEL BI-FUNCTIONAL FUSION PROTEINS EXPANDING THE BOUNDARIES OF BIOLOGIC MEDICINES We obtained the data used throughout this presentation from our own internal estimates and research, as well as from research, surveys and studies conducted by third parties. Internal estimates are derived from publicly available information released and our own internal research and experience, and are based on assumptions made by us based on such data and our knowledge, which we believe to be reasonable. In addit ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

Shattuck Labs, Inc. (NASDAQ:STTK) Q4 2022 Earnings Conference Call February 23, 2023 4:45 PM ET Company Participants Conor Richardson - Vice President, Investor Relations Taylor Schreiber - Chief Executive Officer and Scientific Co-Founder Lini Pandite - Chief Medical Officer Andrew Neill - Chief Financial Officer Conference Call Participants Jonathan Miller - Evercore ISI Marc Frahm - Cowen Yigal Nochomovitz - Citi Zhiqiang Shu - Berenberg Operator Good afternoon, ladies and gentlemen. Welcome to the Shatt ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39593 Shattuck Labs, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or orga ...

Financial Data and Key Metrics Changes - As of September 30, 2022, the company reported cash and cash equivalents and investments of approximately $185.1 million [30] - Research and development expenses for Q3 2022 were $18.9 million, an increase from $15.1 million in Q3 2021 [30] - General and administrative expenses rose to $6.6 million in Q3 2022 from $4.3 million in Q3 2021 [30] - The net loss for Q3 2022 was $24.6 million, or a loss of $0.58 per share, compared to a net loss of $17.4 million, or $0.41 per share, in Q3 2021 [30] Business Line Data and Key Metrics Changes - The lead program, SL-172154 (154), completed enrollment in the monotherapy dose escalation portion of its Phase I trial for advanced platinum-resistant ovarian cancer [10][21] - In Q3 2022, the company began enrolling patients in the first chemotherapy combination cohort for 154, selecting a starting dose of 3 mg/kg [11] - The second clinical stage compound, SL-279252 (252), is in Phase I development for advanced solid tumors and lymphomas, with top-line data expected in Q1 2023 [14][27] Market Data and Key Metrics Changes - The company is focusing on the platinum-resistant ovarian cancer market, where the single-agent response rate for liposomal doxorubicin is typically 10% to 12% [12] - The clinical trial for 154 in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) is expected to begin enrolling patients in Q4 2022 [12][25] Company Strategy and Development Direction - The company aims to differentiate 154 from other CD47 inhibitors by combining CD47 blockade with CD40 agonism, potentially leading to improved response rates [13] - The GADLEN platform is being developed alongside the ARC platform, with a focus on harnessing gamma delta T cells in cancer therapy [15][16] - The company is strategically positioned to fund operations into the second half of 2024, maintaining strong financial discipline [31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical execution and the upcoming key milestones for 154 and 252, with significant data expected in 2023 [32][34] - The company believes that the combination of experienced team, innovative science, and financial resources positions it strongly for future growth [34] Other Important Information - The company has made progress in its preclinical pipeline, with multiple publications on its ARC and GADLEN programs [15] - Initial clinical data from the 154 program is expected to be reported mid-2023 [21][33] Q&A Session Summary Question: Update on the 3 mg and 10 mg doses for the combination trial - Management confirmed that the 3 mg/kg dose is solid for evaluation in combination, supported by pharmacokinetic and pharmacodynamic analyses [38] Question: Infusion reactions and dosing time - The company is using a longer infusion time of over two hours for the combination trials to mitigate infusion reactions [40] Question: Toxicity at the 10 mg/kg dose - The decision to not pursue the 10 mg/kg dose was based on pharmacokinetic and pharmacodynamic analyses, showing no significant benefit over the 3 mg/kg dose [46] Question: Thoughts on CD47 inhibitors and recent abstracts - Management noted that the trends in CD47 inhibitors are evolving, particularly in the TP53 mutant AML population, and emphasized the need for detailed data to assess efficacy [50] Question: Patient expectations for AML and MDS trials - The company anticipates enrolling between 10 and 20 patients across the dose escalation for both monotherapy and combination cohorts [56] Question: Combination with venetoclax - The dose escalation will initially focus on azacitidine, with plans for an expansion cohort that includes venetoclax later [57] Question: GADLEN platform and potential partnerships - The GADLEN platform is broad, and while there are opportunities for partnerships, the company is currently focused on independent development [66]